Background: Two new therapies for fecal incontinence (FI) are now available: non-animal stabilized hyaluronic acid and dextranomer copolymer (NA-SHA/Dx) and sacral nerve stimulation (SNS).
INTRODUCTION
Fecal incontinence (FI) is a socially devastating condition of varied origin. Conservative therapy (CT) includes dietary changes, bulking agents, antidiarrheal medications, enemas, and biofeedback. Contingent on the severity of the incontinence, these noninvasive measures are often initial options. Conservative therapy can successfully improve FI in 430% to 50% of affected individuals. [1] [2] [3] [4] When CT is unsuccessful, other therapies may be considered. Anal sphincter repair, artificial bowel sphincter, muscle transfers, radiofrequency, and stomas are other treatment options for FI available in the United States. Historically, repair of anterior defects was favored; however, more recent research has revealed poor long-term results. 5, 6 Although an attractive alternative with often impressive long-term functional results, artificial bowel sphincter was found to have a 40% major infection rate, limiting its appeal. 7, 8 Muscle transfers are complex and associated with a high morbidity; thus, they have not been widely popularized. Radiofrequency collagen reformation is a promising modality but requires an anesthetic and an operating room or endoscopy suite for its application. A diverting stoma allows affected patients to function away from the toilet but interferes with their overall quality of life. More recently, 2 therapies for FI have been approved by the US Food and Drug Administration (FDA), including non-animal stabilized hyaluronic acid and dextranomer copolymer (NASHA/Dx*), approved in May 2011, and sacral nerve stimulation (SNS † ), approved in March 2011. NASHA/Dx is a bulking agent that consists of dextranomer microspheres in stabilized hyaluronic acid, which are injected into the submucosa. In the prospective randomized study conducted for FDA approval of NASHA/Dx, 52% of patients had a 450% reduction of FI versus 31% of sham-treated patients after 6 months (P ¼ 0.009). 4 These results were sustained in the NASHA/Dx treatment group at 36 months. 9 A separate 24-month follow-up study evaluated the effectiveness of NASHA/Dx for FI under open-label conditions; 62.7% of the patients were treatment responders and experienced at least a 50% reduction in the total number of FI episodes. 10 SNS has also produced major clinical benefits for patients with FI. [11] [12] [13] [14] [15] This therapy involves the administration of long-term low-level electrical impulses to stimulate the sacral sensory and motor fibers. The SNS procedure is a staged process in which the patient first undergoes insertion of an electrode attached to an external pulse generator to assess benefit. If there is a 450% reduction in FI, a permanent electrode is inserted and connected to an implanted pulse generator. The mechanism of action of SNS includes local sensory improvement, probably secondary to cortical stimulation. 16 In the 12-month study conducted for FDA approval of SNS, 90% of patients passed test stimulation and proceeded to long-term implantation; for those patients who received permanent implantation, 83% had therapeutic success, with 41% achieving complete continence. 15 In a long-term study of SNS, Hull et al 17 found
sustained success, with 89% having a 450% reduction in FI at Z5 years and 36% having complete resolution of FI. Considering the various treatment interventions for individuals in whom CT fails and the associated cost burden, a number of studies of the cost-effectiveness of interventions with SNS for FI have been performed. [18] [19] [20] [21] [22] [23] [24] In most cases, SNS was cost-effective, dominating in one Markov analysis from the Netherlands. 24 A simulation model evaluating the costeffectiveness of SNS treatment for FI in patients with an intact anal sphincter estimated an incremental costeffectiveness ratio (ICER) of €38,662 per qualityadjusted life-year (QALY) gained in the Italian health care system. 18 A similar simulation model developed to assess the cost-effectiveness of SNS treatment for a comparable patient population in the Spanish health care system yielded an ICER of €16,181 per QALY gained with minimal budget impact. 21 This latter model was validated using a prospective comparison of 2 patient cohorts. 23 The exception was a study from France comparing 2 patient cohorts; that study found significantly higher ICERs. 22 Patients with FI who underwent implantation with sacral nerve modulation experienced improved disease-related quality of life when compared with patients without implants, but at an increased cost. For the FI patients, the 12-and 24-month ICERs were €90,082 and €185,160, respectively. Although studies have investigated the costeffectiveness of SNS, there is no published literature evaluating the cost-effectiveness of NASHA/Dx. In addition, no comparison has been made between these 2 treatment options to guide health care professionals in choosing one treatment option over the other for affected patients. The objective of the present study was to determine the cost-effectiveness of NASHA/Dx compared with SNS after failure of CT in the United States.
METHODS
A modified decision tree was used to analyze costs and QALYs for adult patients who have had FI symptoms for at least 12 months and did not respond adequately to CT. 4, 15 Figure 1 depicts the primary model structure. The analytic viewpoint was that of the US health care payer during a 3-year period.
Model Structure
A hybrid model was developed to compare costs and outcomes between NASHA/Dx with other options after CT failure. The modeling procedure was guided by the published literature and a panel of clinical experts in this field. To determine suitable treatment options, a literature review was performed, followed by a survey of practicing clinicians (see the Supplemental Survey 1 in the online version at http://dx.doi.org/10.1016/j.clinthera.2014.04. 010). That survey was undertaken at the 23rd Annual International Colorectal Disease Symposium (Fort Lauderdale, Florida, February 2012). The questionnaires captured physician experiences and preferences regarding the testing, diagnosis, and treatment of FI. The survey was fielded to 50 clinicians, and 35 surveys were returned and analyzed (ie, 70% response rate). The survey responses indicated that SNS and NASHA/Dx were suitable treatment options. This information was used to construct the model, which reflected US practice.
The options for this analysis included continuing to receive CT (ie, the "do nothing" option), using NASHA/Dx, and undergoing SNS. Typically, CT involves dietary changes, bulking agents, antidiarrheal medications, glycerin suppositories, enemas, biofeedback, and other noninvasive measures.
1-4 NASHA/Dx requires Z1 injections of dextranomer microspheres in stabilized hyaluronic acid into the submucosa, whereas SNS involves the surgical implantation of a stimulation device under the skin to modulate neuronal impulses. All treatment arms have an initial 6-month treatment phase ( Figure 1 ) followed by Markov submodels that are 30 months in length, for a total period of 3 years ( Figure 2) . The cycle length is 1 month, which is based on having a reasonable period for a series of biofeedback treatments for FI. A half-cycle correction was not used for the Markov submodels because of the relatively short cycle length. Baseline medical management costs for patients with FI were estimated from the published literature. 25 On the basis of physician guidance, biofeedback was included as a potential downstream treatment option for patients who did not achieve primary treatment success with NASHA/Dx or SNS. The model structures for CT and NASHA/Dx were identical; the SNS arm contains 
Clinical Inputs
PubMed was reviewed for relevant studies pertaining to these interventions for the years 2004 to 2013. For the SNS group, PubMed was searched for the title keywords sacral nerve stimulation and fecal incontinence. For the NASHA/Dx group, PubMed was searched for the title keywords NASHA/Dx or hyaluronic acid and fecal incontinence or faecal incontinence. At the abstract level, it was required that studies reported the Responder 50 end point for primary patient data. At the title level, the search resulted in 59 articles for SNS and 6 for NASHA/Dx. One study was not indexed on PubMed and was provided by an adviser. 9 After the studies were reviewed at the abstract level, 9 remained for SNS and 5 for NASHA/Dx. After review at the manuscript level, 5 studies were used to provide data for the SNS group, and 5 studies were used to provide data for the NASHA/Dx group. The efficacy estimates were computed for 12, 24, and 36 months for SNS. 13, 15, [26] [27] [28] The efficacy estimates were computed for 6, 12, 24, and 36 months for NASHA/ Dx. 4, 9, 10, 29, 30 The sample size weighted means were computed using the study sample sizes and the proportions of individuals who met the Responder 50 end point at the respective time points. The efficacy estimate for the stimulation phase of SNS was derived from a multicenter prospective study. 13, 15 
Costs
Because the perspective is that of the health care payer, indirect costs were not included in the model. All direct costs were expressed in 2013 US dollars. The cost estimate for CT was drawn from a published study that reported the mean per person direct medical costs associated with FI. 25 These costs include physician visits, laboratory tests, operations, hospitalizations, medications, and home health care. 25 Since this cost was published using 2010 US dollars, it was adjusted to 2013 US dollars using the medical component of the Consumer Price Index values for mean yearly change. [31] [32] [33] For NASHA/Dx, the cost was provided by the manufacturer (Salix Pharmaceuticals, Raleigh, North Carolina). Because a specific Current Procedural Terminology or Healthcare Common Procedure Coding System code for anoscopy with injection of NASHA/Dx does not currently exist, an estimated charge was developed using crosswalks to similar gastrointestinal endoscopic procedures. Unit costs assigned to resources consumed were derived from Centers for Medicare and Medicaid Services sources, as available (Table II) . [34] [35] [36] Physician reimbursement (under a dedicated Current Procedural Terminology code) for the NASHA/Dx procedure was not currently available from Centers for Medicare and Medicaid Services; therefore, an estimated cost was assumed using similar procedures and guided by expert opinion. Biofeedback and the associated cost were included for treatment nonresponders for the last 30 months of the model. The cost of medical management was included in the last 30 months for all patients. This cost of medical management is the same value that is used for CT as previously noted. 25 For the SNS and NASHA/Dx treatment arms, the medical management costs were decreased by 50% for patients who achieved treatment success. All costs and outcomes were discounted at 3% per annum, as per current recommendations. 37 
Outcomes
Outcome measures of effectiveness were QALYs and IFDs. Quality-of-life values (utility values) were assigned based on whether the patient was experiencing FI symptoms during the model period ( Table I) . QALYs were not derived directly from studies of NASHA/Dx or SNS because generic health preference outcomes were not available. Values were derived from published studies that evaluated European Quality of Life-5 Dimensions scores and estimated utility values for FI patients dependent on their symptomatic status. 18, 38 A utility value of 0.55 was assigned for periods associated with FI symptoms, whereas a utility value of 0.74 was assigned for periods associated with adequate relief of FI symptoms, which was defined as success with respect to the Responder 50 end point.
Statistical Analysis
The economic outcome of the analysis was the ICER for each of the outcomes of interest, which were ‡ Where multiple estimates were available from more than one study, a weighted mean was computed (weighted by sample size). In cases where multiple estimates were not available, the estimate from only one study was used. For 1 year and 3 years, the weighted mean estimates were the estimates used in the models. § The test stimulation phase is relatively short (usually 10-14 days).
expressed as the incremental cost per QALY gained and per IFD gained during the 3-year period. To evaluate the robustness of model outcomes, 1-way sensitivity analyses were performed for cost inputs, probabilities, and utilities. For 1-way sensitivity analyses, plausible ranges were used to investigate the effect of deviations on a per variable basis. One-way sensitivity analyses were presented in ICER tornado diagrams (Figures 4-6 ). One-way sensitivity analyses were computed for the NASHA/Dx cost input, the decrease in medical management costs for treatment responders in the NASHA/Dx and SNS arms, and the NASHA/Dx subsequent treatment rate (Tables V-VII) .
A probabilistic sensitivity analysis was performed to evaluate the overall variability of model outcomes using 10,000 iterations. The SEs for the probability values were estimated using the formula for binomial proportions and were used as the measure of variability in the probabilistic sensitivity analysis. Cost inputs were modeled as lognormal distributions, and probability and utility variables were modeled as β-distributions (see the Supplemental Table I in the online version at http://dx.doi.org/10.1016/j.clinthera.2014.04.010). Sensitivity analyses were presented in ICER tornado diagrams. The range for the utility value (0.63-0.85) for treatment success was taken from a published study 18 that evaluated the cost-effectiveness of sacral neuromodulation for FI.
A cost-effectiveness acceptability curve was computed to evaluate the relationship between willingnessto-pay (WTP) thresholds and the likelihood of an intervention being cost-effective ( Figure 3 ). For this curve, the sum of the respective probabilities is 1 for the range of WTP values. The WTP threshold ranges from 0 to $100,000. The net monetary benefit is used for the computations. The percentage of iterations favoring each intervention with respect to a range of WTP thresholds is presented (see the Supplemental Table II in the online version at http:// dx.doi.org/10.1016/j.clinthera.2014.04.010).
Budget Impact Analysis
A budget impact analysis (BIA) was performed to estimate the effect of FI treatment with NASHA/Dx and SNS on health care plan costs. The noninstitutionalized population of US adults was used as the base population, with estimates of the prevalence of FI (ie, 2.7%) derived from published sources. 39, 40 Effect estimates were based on a health care plan with 1,000,000 covered lives. NASHA/Dx is a relatively new intervention; hence, its use is not well known. The proportion of the population who seek care is 25%, and an estimated 80% of this population will initially be treated with CT. 18 The estimated CT failure rate was 25%. 18 The BIA was performed using a range of 5% to 25% for the likelihood that patients would choose or be assigned to NASHA/Dx. The BIA is computed for patients who are good candidates for both NASHA/Dx and SNS. The net effect to the health care payer is computed for the scenario when all patients receive NASHA/Dx, for a scenario when all patients receive SNS, and for a set of intermediate scenarios. The BIA was performed using Microsoft Excel 2010 (Microsoft Corp).
RESULTS
The cost-effectiveness models evaluated 2 end points: QALYs and IFDs. For the 3-year cost-effectiveness models (for both outcomes), the costs for CT, NA-SHA/Dx, and SNS were $9053, $14,968, and $33,201, respectively (Table III) . Total IFDs during the 3-year periods associated with CT, NASHA/Dx, and SNS were 128.8, 267.6, and 514. The cost-effectiveness acceptability curve presents the likelihood that the interventions are cost-effective over a range of WTP thresholds ( Figure 3 , Supplemental Table II in the online version at http://dx.doi.org/10.1016/j.clinthera.2014.04.010). For NASHA/Dx, 59% of simulations would be costeffective at a WTP threshold of $50,000 and 63% at a WTP of $100,000. At a WTP of $40,000 per QALY, 53% of the simulations for NASHA/Dx would be costeffective, which is slightly higher when compared with CT (46%). In comparison, SNS had only a 3% probability of cost-effectiveness at a WTP of $50,000 and 16% at $100,000.
The BIA was computed for a range of ratios for the use of NASHA/Dx and SNS. When all of the patients receive NASHA/Dx, the net annual effect to the health care payer budget ranged from $571,455 to $2,857,275 (Table IV) Clinical Therapeutics net annual effect to the health care payer budget ranged from $1,959,323 to $9,796,613. Intermediate scenarios, where the use of both NASHA/Dx and SNS range from 25% to 75%, are also presented. Because the acquisition cost of NASHA/Dx is significantly less than SNS, the scenarios that favor more use of NASHA/Dx present less net effect to the health care payer.
Results of the 1-way sensitivity analysis computed for the NASHA/Dx treatment cost appear in Table V . The base case cost for the NASHA/Dx treatment was $4900, and this value ranged from $2940 to $6860. Under this range of scenarios, the incremental cost per additional QALY gained for NASHA/Dx versus CT ranged from $16,986 to $57,086. The incremental cost per additional QALY gained for SNS versus NASHA/Dx ranged from $287,458 to $201,560.
Under all scenarios, the incremental cost per QALY gained for NASHA/Dx was significantly less than the comparable value for SNS.
A 1-way sensitivity analysis was computed for the decrease in medical management costs for treatment responders ( Table VI) . The base case cost for the percentage of decrease in medical management costs for treatment responders was 50%; this value ranged from 0% to 50% in the sensitivity analysis. Under this range of scenarios, the incremental cost per additional QALY gained for NASHA/Dx versus CT ranged from $22,005 to $37,036. The incremental cost per additional QALY gained for SNS versus NASHA/Dx ranged from $244,036 to $244,509. Under all scenarios, the incremental cost per QALY gained for NASHA/Dx was significantly less than the comparable value for SNS. A 1-way sensitivity analysis was computed for the NASHA/Dx subsequent treatment rate ( Table VII) . The base case for the retreatment rate is 63.4%, and this value ranged from 33% to 82% in the sensitivity analysis. Under this range of scenarios, the incremental cost per additional QALY gained for NASHA/Dx versus CT ranged from $27,175 to $43,069. The incremental cost per additional QALY gained for SNS versus NASHA/Dx ranged from $231,586 to $265,631. Under all scenarios, the incremental cost per QALY gained for NASHA/Dx was significantly less than the comparable value for SNS.
The tornado diagrams for the ICERs indicate the variables that have the most effect on the incremental costs per QALYs gained (Figures 4-6) . In all cases, the variable that is most able to influence the ICERs is the utility value for treatment success. For the ICER for NASHA/Dx versus CT, the next 2 most influential variables are the cost for the NASHA/Dx treatment and the utility value for nonresponders (ie, treatment failure). The expected value for the ICER in this sensitivity analysis ranges from approximately $10,000 to $100,000 per incremental QALY gained (Figure 4) . For the ICER for SNS versus NASHA/Dx, the next 2 most influential variables were the success rate for the SNS implantation procedure and the NASHA/Dx success rate. The expected value for the ICER in this sensitivity analysis ranges from approximately $150,000 to $600,000 per incremental QALY gained ( Figure 5 ). For the ICER for SNS versus NASHA/Dx, the next 2 most influential variables were the utility value for nonresponders (ie treatment failure) and the SNS permanent implantation cost. The expected value for the ICER in this sensitivity analysis ranged from approximately $60,000 to $260,000 per incremental QALY gained ( Figure 6 ).
DISCUSSION
Fecal incontinence imposes a substantial health and economic burden on the US population; the estimates of the prevalence of this condition in some form have been as high as 24% in the general population but generally range from 2% to 8%. [39] [40] [41] [42] For physicians and patients, there will undoubtedly be a variety of factors that affect decisions related to treatment options when CT has been proven unsatisfactory. From the patient's point of view, the less invasive nature of the NASHA/Dx injectable and the favorable adverse event profile may make it an attractive intermediate option between CT and surgical options (eg, anal sphincteroplasty and sacral nerve stimulation). From the payers' point of view, FI exerts a substantial economic effect on the health care system. The costs associated with CT for FI (eg, dietary changes and biofeedback) are relatively low when compared with the costs associated with the treatment options when CT is not sufficiently effective. In the United States, the currently available treatment options after CT failure are NASHA/ Dx, SNS, and anal sphincteroplasty. Although the costs associated with NASHA/Dx are not insignificant, they are 60,000 80,000 100,000 120,000 140,000 160,000 180,000 200,000 220,000 240,000 260,000 Figure 6 . Tornado Diagram (ICER for SNS vs CT). NASHA/Dx = non-animal stabilized hyaluronic acid and dextranomer copolymer; SNS = sacral nerve stimulation; CT = conservative therapy; ICER = incremental cost-effectiveness ratio; Trt = treatment; Phys = physician; Imp = implantation; EV = expected value; Stim = stimulation.
much less than for surgical treatment. When compared with SNS, the acquisition cost for the first treatment of NASHA/Dx represents only 18% of the cost for full SNS implantation. If subsequent treatment for all patients is assumed, the costs for NASHA/Dx still only represent approximately 36% of the SNS cost. Considering the high prevalence and economic burden, as well as the associated negative effect on 44 this analysis provides "moderate evidence for adoption and appropriate utilization" of this new technology. They also indicated that its cost-effectiveness would be comparable to that of hospital hemodialysis compared with ambulatory peritoneal dialysis. In contrast, SNS had only a 3% probability of cost-effectiveness at a WTP of $50,000 and 16% at $100,000. The BIA presents the additional costs to the health care system for patients who are good candidates for both NASHA/Dx and SNS. The BIA models the input variables over relatively wide ranges because the realworld use of NASHA/Dx is not yet well understood. Initially, NASHA/Dx accrues additional costs for the health care system; however, this intervention may be able to provide satisfactory results for at least 50% of patients in whom conservative medical management fails. NASHA/Dx may provide an opportunity for the health care payer to positively affect the health status of their patients and also potentially lessen net expenditures. Because some patients may be unwilling to undergo the risks associated with surgical treatment, this technology may represent an opportunity for health benefits for these patients. Sensitivity analyses indicate that the cost-effectiveness results (for the incremental costs per QALY gained) are robust with respect to moderate deviations in input values that underlie the value of the NASHA/Dx to the health care payer. The ICERs for NASHA/Dx, for the range of sensitivity analyses investigated, all fall within the range acceptable for the adoption of a new technology. The favorable cost-effectiveness of NASHA/Dx for both outcomes reflects the increased benefits to the patient, which can be acquired for a lower cost. Some patients may not be able to achieve adequate outcomes using NASHA/Dx; consequently, they may elect to proceed to surgical options, such as SNS.
Because both of these technologies have been approved by the FDA as recently as 2011, the availability of long-term data is limited. What currently exist are largely follow-up data from the clinical trials. This analysis used results from clinical trials, which may limit the generalizability to real-world practice. For NASHA/Dx, the length of follow-up available in the literature was limited to 3 years, hence the period for this model. For SNS, most of the data available from the literature is r3 years. However, a few studies have reported data that report the efficacy during at least 5 years. 17, 43 The efficacy estimates for these studies range from 74% to 89%. An additional study 45 reported the efficacy of SNS treatments for FI for a median follow-up duration of 114 months; in this study 48% of the patients maintained full continence. These studies represent some evidence of the durability of effect for SNS treatments. The durability of effect for NASHA/Dx treatments needs to be evaluated in future research. One consideration that may be important is the need for battery replacement for the SNS procedure, which typically occurs 3 to 5 years after the procedure and adds to the overall costs and any potential complications associated with replacement. Although this example is stated for SNS, there may also be important longterm considerations related to NASHA/Dx that have not been included in this analysis. Only 2 of the referenced studies included a control group; therefore, the efficacy estimates for NASHA/Dx and SNS have been estimated directly from the literature and have not been standardized through a common comparator.
Another limitation lies in the limited number of clinical outcomes that are incorporated into this economic analysis. This analysis is built on the Responder 50 end point and the number of IFDs. These end points likely capture a large portion of the improvement in FI; however, there are other end points that complement the understanding provided by these outcomes. For instance, the disease-specific quality-of-life instruments, including the Fecal Incontinence Quality of Life Scale, are sensitive to improvements in FI patients' quality of life; however, methods for quantifying this improvement within the context of an economic analysis have not yet been established. The present analysis provides the patient, physician, and payer with a potential pathway for the management of FI for patients whose conditions are not well controlled with CT. When considering the 2 options when CT fails, NASHA/Dx should be considered as the first option because it provides a less invasive and lower cost intervention, which also has the benefit of reducing by 450% the population who may proceed to SNS.
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